Company performance
Add to research
Current Price
as of Mar 13, 2025$2.84
P/E Ratio
N/A
Market Cap
$24.05M
Loading...
Description
Add to research
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Metrics
Add to research
Overview
- HQLexington, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerCRIS
- Price$2.84+7.98%
Trading Information
- Market cap$24.05M
- Float88.19%
- Average Daily Volume (1m)30,194
- Average Daily Volume (3m)102,909
- EPS-$7.81
Company
- Revenue$10.26M
- Rev growth (1yr)3.46%
- Net income-$10.09M
- Gross margin97.17%
- EBITDA margin-358.44%
- EBITDA-$10.51M
- EV$50.42M
- EV/Revenue4.91
- P/EN/A
- P/S1.64
- P/BN/A
- Debt/EquityN/A
Documents
Add to research
SEC Filings
Factset Street Account